Skip to content

Treatment of patients with ZCL

The effect of MJ1 (Topical dairy extract) versus routine care for treatment of cutaneous leishmaniasis (rural) in Isfahan Iran :a randomized controled clinical trial (RCTs)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013092414746N1
Enrollment
196
Registered
2014-02-20
Start date
2013-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zoonotic cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: In this group patients apply MJ1 skin cream 3 times a day, they are trained to use it for a month with a diameter of 3 mm on the rub of the lesion without dressing. Intervention 2: S
Treatment - Drugs
In this group patients apply MJ1 skin cream 3 times a day, they are trained to use it for a month with a diameter of 3 mm on the rub of the lesion without dressing.
Skin cream MJ1 - 3 times a day - for a month

Sponsors

Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The inclusion criteria Patients can be enrolled : • Cutaneous leishmaniasis of Parasitology confirmed that they have not been previously treated . • have any other medical problem ( such as heart disease , renal, hepatic , or hematologic ) • Being available for follow up. • Give informed consent to participate in the study . Exclusion Criteria • Since the drug is completely non -synthetic and natural origin and do not appear to have adverse side , but in people with a history of allergic reactions, severe skin is not used. • The use of drugs , sex and no age restrictions and is not contraindicated in pregnancy . • In patients who are treated for secondary infections are excluded. Patients who are excluded are routinely treated .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Lesion size, lesion diameters measured. Timepoint: 1, 2, 3, 4 and 8 weeks after starting treatment, patients are evaluated. Method of measurement: At each visit, the two dimensions are measured and calculated it as a square. Lesion size by measuring the lesion diameter is measured.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Janghorbani

Isfahan University of Medical Sciences

janghorbani@hlth.mui.ac.ir+98 31 1792 2774

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026